Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
October 17, 2023
Assignee:
Novo Nordisk A/S
Inventors:
Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
Abstract: The present invention provides codon optimized Factor VIII sequences, vectors and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.
Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.
Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing influenza virus activity, thus providing a means of treating or preventing influenza infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the influenza HA for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
Type:
Grant
Filed:
January 24, 2019
Date of Patent:
October 10, 2023
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
Lisa A. Purcell, Jonathan Viau, William Olson
Abstract: The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
Type:
Grant
Filed:
February 16, 2021
Date of Patent:
October 3, 2023
Assignee:
MEDIMMUNE LIMITED
Inventors:
Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
October 3, 2023
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE STRASBOURG, ETABLISSEMENT FRANçAIS DU SANG (EFS)
Abstract: The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.
Type:
Grant
Filed:
August 19, 2021
Date of Patent:
September 26, 2023
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Dana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee
Abstract: Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
Type:
Grant
Filed:
February 21, 2019
Date of Patent:
September 19, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Paolo Lusso, Qingbo Liu, Peter Kwong, John Mascola, Young Do Kwon
Abstract: The disclosure provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.
Type:
Grant
Filed:
July 6, 2018
Date of Patent:
September 12, 2023
Inventors:
Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.
Abstract: The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.
Abstract: Provided is an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Type:
Grant
Filed:
December 9, 2020
Date of Patent:
August 15, 2023
Assignee:
Rallybio IPA, LLC
Inventors:
Terje Michaelsen, Oistein Ihle, Tor Brynjar Stuge, Anne Husebekk, Heidi Tiller, Mariana Eksteen, Bjorn Ragnar Skogen
Abstract: Provided are antibodies or antigen binding polypeptides characterized by the ability to neutralize respiratory syncytial virus (RSV). Specifically, the antibodies or antigen binding polypeptides are characterized by high affinity binding to RSV fusion glycoprotein (RSVF). Further provided are methods for their identification, isolation, generation, preparation, and use, as well as the heavy chain and light chain sequences of the antibodies provided.
Abstract: The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides.
Abstract: The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles having low internal void spaces comprising bioactive therapeutic agents.
Type:
Grant
Filed:
June 18, 2021
Date of Patent:
August 8, 2023
Assignee:
Elektrofi, Inc.
Inventors:
Paul Brown, Lyndon Fitzgerald Charles, Jr., Chase Spenser Coffman, Daniel Benjamin Dadon, James Ivey, Lisa Liu, Chaitanya Sudrik
Abstract: A method for producing an examination reagent includes adding a helper ligand to a receptor protein which is unfolded in an initial solution so as to provide a pre-solution of the examination reagent with a receptor protein which is folded. The receptor protein which is folded comprises a bonded helper ligand which can be exchanged with an examination peptide.
Type:
Grant
Filed:
July 1, 2019
Date of Patent:
July 11, 2023
Assignee:
CONSTRUCTOR UNIVERSITY BREMEN GGMBH
Inventors:
Sebastian Hartmut Springer, Sunil Kumar Saini
Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
Type:
Grant
Filed:
February 2, 2018
Date of Patent:
July 4, 2023
Assignees:
Acticor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National de la Santé et de la Recherche
Médicale), Université Paris-Saclay
Inventors:
Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
Abstract: Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.
Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
May 30, 2023
Assignees:
Merck Sharp & Dohme LLC, Adimab, LLC
Inventors:
Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz